Introduction
In multiple myeloma (MM), enhanced proliferation and increased resistance to apoptotic stimuli account for the expansion of the malignant clone. It is now clear that interleukin-6 (IL-6) can function as a speci®c MM tumor growth factor due to its ability to stimulate both proliferative and survival responses in these cells (Anderson et al., 1989; Lichtenstein et al., 1995) . Further support for IL-6 as a tumor growth factor in vivo includes: (1) IL-6 levels are elevated in plasma and bone marrow of myeloma patients and levels correlate with disease activity Reibnegger et al., 1991; (2) Monoclonal anti-IL-6 antibodies can induce anti-tumor responses in patients (Klein et al., 1991) ; Bataille et al., 1995) , and; (3) IL-6 transgenic mice are prone to developing MM (Suematsu et al., 1992) , while IL-6 knockout mice are resistant (Hilbert et al., 1995) . The source of IL-6 is from the marrow microenvironment which stimulates MM cells in a paracrine fashion .
The crucial signal transduction pathways that induce IL-6 stimulatory eects on MM cells are under intensive study. Previous investigations have implicated the ERK , Jun kinase Xu et al., 1998) , and STAT (Catlett-Falcone et al., 1999) signaling cascades. However, recent studies suggest a signal pathway involving the AKT kinase may also be important in expansion of myeloma clones. AKT is encoded by c-akt, the cellular homologue of the viral oncogene, v-akt, originally identi®ed in an acute transforming retrovirus causing T cell lymphomas in mice (Bellacosa et al., 1991) . AKT is activated as a major target of phosphoinositol 3-kinase (PI 3-kinase)-generated signals (Franke et al., 1995; Stokoe et al., 1997) . Activation requires phosphorylation of AKT on threonine and serine residues (Klippel et al., 1997; Franke et al., 1995) . A newly described membrane bound kinase, 3-phosphoinositide-dependent kinase (PDK1), phosphorylates AKT on threonine residues. The phospholipid second messengers of the PI 3-kinase reaction bind to the pleckstrin homology (PH) domain of AKT and alter its conformation so that threonine residues become accessible to PDK1 (Klippel et al., 1997) . PDK1 is a constitutively active kinase that is membrane-bound due to its own PH domain binding to low basal levels of phospholipids. In contrast, AKT is located in the cytosol of unstimulated cells but translocates to the cell membrane following stimulation (Andjelkovic et al., 1997) . Thus, the upstream PI 3-kinase-generated phospholipid messengers are crucial as they recruit AKT to the membrane (near PDK1) and also facilitate threonine phosphorylation by PDK1. Following threonine phosphorylation, AKT then autophosphorylates itself at serine residues (Toker and Newton, 2000) . Activated AKT may promote oncogenesis by virtue of its ability to activate several distinct downstream pathways which mediate proliferative or survival responses. In fact, the ability of AKT to transform cells (Cheng et al., 1997) , of AKT antisense to inhibit transformation (Cheng et al., 1996) , the presence of ampli®cation/over-expression of AKT in some solid tumors (Cheng et al., 1992; Miwa et al., 1996) and the fact that the PTEN phosphatase, which inhibits AKT activation, is a known tumor suppressor gene (Wu et al., 1998) , all implicate AKT in oncogenesis.
Support for a role of AKT speci®cally in myeloma pathogenesis comes from recent studies which demonstrated that IL-6 can activate AKT in myeloma cells (Tu et al., 2000) , that some myeloma cell lines harbor PTEN loss-of-function mutations with heightened AKT activation (Hyun et al., 2000) , and that the inhibition of myeloma cell growth in vitro could be induced by selective inhibition of PI 3-kinase, the upstream activator of AKT (Tu et al., 2000) . Furthermore, in a recent study, we demonstrated frequent AKT activation in situ in myeloma cells of patient bone marrow (Hsu et al., 2001) . However, there has been no previous assessment of the direct eects of AKT activation or inhibition on myeloma cell growth. We, thus, initiated the current study to test the eects of dominant active or dominant negative AKT constructs on MM cell responses to IL-6.
Results

AKT activation in multiple myeloma cells transfected with active or dominant negative constructs
The AF-10 myeloma cell line was used to investigate the role of AKT activation in IL-6-induced proliferative response. This cell line consistently demonstrates an approximate twofold increase in its proliferative rate when exposed to the MM growth factor IL-6 (Tu et al., 2000) . In addition, we have previously detected AKT activation in AF-10 cells following stimulation with IL-6 (Tu et al., 2000) . A more systematic evaluation of AKT activation in this cell line was undertaken to evaluate its kinetics and wortmannin-sensitivity. As shown in one of several in vitro kinase assays ( Figure  1a ), IL-6 activated AKT activity within 15 min of incubation and activity decreased by 30 min. Pretreatment with the PI 3-kinase inhibitor wortmannin (at 0.1 mM) abrogated AKT activity. IL-6 and wortmannin had no eect on expression of total AKT (bottom panel). These data are consistent with AKT activation occurring downstream of IL-6-induced PI 3-kinase activation. Similar results were obtained by immunoblotting with phospho-speci®c anti-AKT antibody, which recognizes AKT when phosphorylated at serine 473 (Figure 1b , one of ®ve separate experiments). In the immunoblot analysis, phosphorylated AKT was ®rst detected by 5 min, increased by 15 min, and was completely abrogated by pre-treatment with 0.1 mM wortmannin. Wortmannin, again, had no eect on expression of total AKT (bottom panel). Furthermore, this concentration of wortmannin was speci®c for inhibiting AKT activation and AKT phosphorylation as it had no eect on IL-6-induced phosphorylation of p42 and p44 ERK in the same cells (Tu et al., 2000) .
The above ability of wortmannin to prevent IL-6-induced AKT activation in AF-10 cells correlated with a signi®cant (P50.05) inhibitory eect of the drug on IL-6-induced stimulation of proliferation. Whereas the mean IL-6-dependent proliferation index (assayed at 72 h) in control AF-10 cells was 2.2+/70.4 (mean+/7 of four experiments), wortmannin at 0.1 mM signi®-cantly (P50.05) inhibited IL-6-induced cell growth (proliferation index of 1.3+/70.2). These data are similar to the previously demonstrated inhibitory eect of wortmannin on IL-6-dependent AF-10 cell growth (Tu et al., 2000) and support a role for PI 3-kinase in the IL-6 proliferative response. To speci®cally investigate the role of AKT in IL-6-stimulated proliferation, we exploited the susceptibility of myeloma cells to adenovirus transfection (Teoh et al., 1998; Prince et al., 1998) . We transfected cells with an active AKT construct that exhibits enhanced activity or a dominant negative AKT that inhibits endogenous activity. As an active AKT, we utilized the AKT-E40K mutant that possesses enhanced activity due to a point mutation resulting in an increased anity of the PH domain for the second messenger phospholipids (Aoki et al., 1998) . In addition, the E40K could potentially respond to physiological stimuli, like IL-6 (Aoki et al., 1998 ). An adenoviral vector expressing the enhanced green uorescent protein (EGFP) was used which allowed us to con®rm the sensitivity of AF-10 cells to adenoviral transfection. At an MOI of 10, transfection of AF-10 cells with either E40K or control vector resulted in 490% transfection eciency. Cells were infected with the`E40K' adenovirus at either 10 or 25 MOI, or the control virus only expressing EGFP at an MOI of 25. As shown in Figure 2a , the EGFP control-transfected control cells were still capable of modest AKT phosphorylation when exposed to IL-6 for 20 min. In AF-10 cells transfected with the`E40K' construct, a much higher level of total and phosphorylated AKT was expressed and the amount expressed correlated with the MOI used (compare E MOI 25 to E MOI 10 in Figure 2a ). IL-6 was capable of only a modest further increase in AKT phosphorylation in cells transfected at MOI 10. By densitometric analysis, IL-6 induced a 2.3-fold increase in AKT phosphorylation (mean of three experiments) at 20 min in AF-10 cells transfected with E40K at MOI 10. After transfection with E40K at MOI 25, there was little eect of IL-6, possibly because of a higher basal AKT phosphorylation.
To inhibit endogenous AKT activity, we infected AF-10 cells with a virus expressing the HA-tagged pleckstrin homology (PH) domain of AKT using the same adenoviral vector. In other models, this Nterminal regulatory domain of AKT functions as a dominant-negative (DN) to inhibit endogenous AKT activity (Soonyang et al., 1997) . Again, using MOIs as low as 10 and 25, we con®rmed successful expression in 490% of cells (by EGFP¯uorescence) in both groups of transfected cells. Following adenoviral infection with an MOI of 10, AF-10 MM cells were treated with or without IL-6. Anti-HA immunoblots con®rmed expression of the truncated PH construct and the ability of PH to inhibit IL-6-induced AKT activity was demonstrated by in vitro kinase assay (Figure 2b ). Similar eective inhibition of IL-6-induced AKT kinase activity was achieved with an MOI of 25 (not shown).
Role of AKT in IL-6-dependent proliferation AF-10 cells were ®rst transfected with the active E40K construct (vs EGFP control) and, 24 h later, treated with or without IL-6. At varying time points after addition of IL-6, cell recovery was determined by Trypan blue and MTT assays. As shown in Figure 3 , there was a signi®cant (P50.05) increase in cell recovery induced by transfection of the E40K construct. At 48 h, there was a 64% increase (3.6 vs 2.2610 5 , means of four separate experiments) and, at 72 h of culture, a 43% increase (4.8 vs 3.35610 5 cells). The MTT assay gave comparable results with a 55% increase in OD (E40K4EGFP control) at 48 h and 48% increase at 72 h (data not shown). There was no dierence in the per cent viability (by dye exclusion assay) between the two groups at either time point. Interleukin-6 increased cell growth in both control and E40K-transfected cells. Although cell recovery by Trypan blue or MTT assays was signi®cantly (P50.05) higher in IL-6-treated E40K-expressing cells compared to IL-6-treated control cells at both 48 and 72 h, the proliferation indices (PIs) were comparable. For example, from the results shown in Figure 3 in one of four separate experiments, the PIs for EGFP and E40K transfected cells at 48 h were 1.82 and 1.72, respectively and, at 72 h, were 1.85 and 1.75. Similar results were seen when MOIs of 25 were used in this experiment, i.e., signi®cantly higher cell recovery in E40K-transfected cells and comparable IL-6 proliferation indices (data not shown). We next transfected AF-10 myeloma cells with the PH dominant negative AKT (or EGFP control), treated them with or without IL-6, and, 72 h later, recorded the increase in viable cell recovery. There was no signi®cant eect of the dominant negative AKT on viable cell recovery (compared to the control adenoviral infection) in MM cells not exposed to IL-6 (not shown). However, expression of the PH AKT in MM cells inhibited IL-6-induced cell expansion in culture. As shown in Figure  4a , AF-10 cells infected with control adenovirus (dark bars) are not aected in their ability to respond to IL-6, demonstrating a proliferation index of approximately 2, which is comparable to non-infected cells (Tu et al., 2000 , and data not shown). However, AF-10 cells expressing the PH dominant-negative protein (light gray bars) were inhibited in their ability to respond to IL-6 with respect to increased cell growth. Signi®cant inhibition (P50.05) was demonstrated at all MOIs between 10 and 50.
Cell cycle analysis ( Figure 4b ) con®rmed that, while expression of the PH dominant-negative AKT protein did not aect cell cycle distribution in AF-10 cells not exposed to IL-6 (compare a to c), it prevented the IL-6-induced increase in proportion of cells in S phase. As shown, the percentage of cells in S phase in controlinfected cells increased from 32% (panel a) to 52% (panel b) by 24 h of exposure to IL-6. In contrast, in PH-transduced AF-10 cells, no IL-6-induced increase was observed (S=27% in media (panel c) versus 25% in IL-6-treated cells (panel d)). This latter experiment was repeated twice with identical results.
Role of AKT in IL-6-dependent protection against apoptosis
To test the role of AKT in IL-6-induced protection against apoptosis, we utilized the 8226 and OCI-My5 MM cell lines. These MM targets express functional IL-6 receptors and exogenous IL-6 protects them against apoptosis (Xu et al., 1998; Lichtenstein et al., 1995) but does not stimulate proliferation. Thus, we can isolate cytokine-induced eects on apoptosis without obfuscating eects on proliferation. In addition, both lines demonstrate IL-6-induced AKT activation (Tu et al., 2000) and both are easily transfected with our adenoviral vectors (490% transfection eciency at MOI of 10). Figure 5a ,d demonstrates the ectopic expression of AKT and phosphorylated AKT in E40K-transfected 8226 and OCI-My5 cells, respectively. IL-6 had a very minimal eect on further increasing AKT phosphorylation in E40K-transfected 8226 cells (approximately 1.46control when MOI 10 was used, Figure 5a ) and no eect on E40K-transfected OCIMy5 cells (Figure 5d ). In contrast, IL-6 was capable of a modest increase in AKT phosphorylation in both control-transfected cell lines. Figure 5c ,e demonstrate eective expression of the PH AKT dominant negative construct in 8226 and OCI-My5 cells, respectively. This was shown by immunoblot detection of the HA-tagged truncated AKT protein. The PH dominant negative was functional in these MM cells, inhibiting IL-6-dependent AKT kinase activity in 8226 cells ( Figure  5b ) and IL-6-induced AKT phosphorylation in OCIMy5 cells (Figure 5d ).
E40K-transfected MM cells were then exposed to dexamethasone, anti-fas or doxorubicin, and assayed at varying intervals for induction of cytotoxicity and apoptosis. There was no eect of E40K expression on sensitivity to cytotoxicity (MTT assay) induced by antifas or doxorubicin. By MTT assay, the LD50 (concentration inducing 50% cytotoxicity) for anti-fas (assayed at 24 h) was 0.2 mg/ml and 0.3 mg/ml for control-transfected and E40K-transfected 8226 cells, respectively. For control-transfected and E40K-transfected OCI-My5 cells, it was 0.3 and 0.4 mg/ml, respectively. The LD50 for doxorubicin (assayed at 72 h) was 0.4 and 0.3 mM for control-transfected and E40K-transfected 8226 cells and 0.2 and 0.1 mM for similarly transfected OCI-My5 cells. These small dierences in LD50s are not signi®cant. A comparable LD50 between control-and E40-transfected cells was also seen when sensitivity to doxorubicin was assayed at 48 h (not shown). An absence of eect of E40K was also seen when we speci®cally assayed maximal apoptosis (anti-fas, 0.5 ± 1 mg/ml at 24 h, serum starvation at 72 h, or doxorubicin, .5 ± 1 mM at 72 h) induced by these conditions using¯ow cytometry for expression of annexin-V (not shown). However, as shown in Figure 6 , expression of E40K signi®cantly protected both MM cell lines against cytotoxicity and apoptosis induced by 10 76 m dexamethasone (Figure 6a,b) . Comparable results were present when apoptosis was assayed by evaluating a sub-G1 peak in propidium iodide (PI)-stained cells (not shown). In addition, the protection against dexamethasone was also present at a lower concentration of drug. At 5610 77 M, dexamethasone induced 32% cytotoxicity (mean+s.d. of three experiments) of control-transfected 8226 cells but only 6% of cytotoxicity of E40K-transfected cells and induced 27% cytotoxicity of control-transfected OCI cells but only 15% cytotoxicity of E40K-transfected cells. When IL-6 (100 U/ml) was added to E40K ± versus control-transfected cells which were challenged with dexamethasone (10 76 M), a comparable degree of cytokine-induced protection was seen in both cell types. For example, in control-transfected 8226 cells, the degree of dexamethasone-induced apoptosis was decreased from 30 to 14% by addition of IL-6. In E40K-transfected 8226 cells, the per cent apoptosis decreased from 14 to 6% when IL-6 was added.
Even though the IL-6 protective eect in E40K-transfected MM cells was equivalent to controltransfected cells, the above data suggested that expression of high amounts of activated AKT could protect MM cells against dexamethasone. However, the level of activated AKT induced by IL-6 in non-transfected cells is much lower than that induced by E40K transfection. Thus, to test whether AKT activity was critical for IL-6-induced protection in these two MM cell lines, we transfected the cells with the dominant negative PH or control adenovirus. Cells were then challenged with dexamethasone and treated with or without IL-6. As shown in Figure 7 , expression of the PH dominant negative AKT had no eect on the ability of IL-6 to protect either 8226 or OCI-My5 cells from dexamethasone. This was true for MTT assays that measured cytotoxicity or¯ow cytometric analysis that measured per cent apoptosis by annexin-V expression (per cent apoptosis shown above the bars in Figure 7) . Thus, although experiments with the E40K construct demonstrate that AKT activation can potentially regulate sensitivity to dexamethasone, at least in these two myeloma cell lines, there are IL-6-induced AKTindependent survival mechanisms generated.
Discussion
The results of this study demonstrate IL-6-induced activation of AKT in multiple myeloma cells and support a role for the kinase in cytokine-dependent myeloma cell expansion. Ectopic expression of an active AKT gene with enhanced kinase activity resulted in a signi®cant increase in viable cell recovery and inhibition of endogenous AKT activation/activity with a dominant negative gene, prevented an IL-6-induced increase in cell cycling. Although enhanced AKT activity signi®cantly protected myeloma cells from dexamethasone-induced apoptosis, inhibition of endogenous activity did not aect the ability of IL-6 to protect these cells from dexamethasone.
Utilizing immunohistochemistry with a phosphospeci®c anti-AKT antibody, we have previously identi®ed a very frequent incidence of AKT activation in myeloma cells in patient bone marrow (Hsu et al., 2001) . The current study as well as our previous report (Tu et al., 2000) and an additional paper by Chen et al., 1999 are all consistent in con®rming the ability of IL-6 to activate AKT. Since myeloma patients are known to express high levels of IL-6 in bone marrow , it is reasonable to indict this cytokine as the stimulus of AKT activation in patient marrow. However, it is possible that other cytokines are equally important. IL-6 is one of several cytokines that stimulate cells through the gp 130 signaling protein. It is, thus, not surprising that other gp 130-signaling cytokines can also activate AKT (Oh et al., 1998) . As many of these other gp 130-dependent cytokines can also stimulate myeloma cell responses in vitro (Zhang et al., 1994) , and are present in vivo, they may also contribute to AKT activation in patient cells. In addition, IGF-1, a known myeloma growth factor and also present in myeloma marrow, potently stimulates AKT activation in myeloma cells (Tu et al., 2000; Hyun et al., 2000) .
The molecular mechanism that mediates IL-6-induced AKT activation in myeloma cells is unclear. In AF-10 cells, activation is wortmannin-sensitive and abrogated by a dominant-negative PI3-kinase construct (Tu et al., 2000) . In addition, IL-6 treatment of hepatocytes rapidly induces tyrosine phosphorylation of p85, the regulatory sub-unit of PI3-kinase (Chen et al., 1999) . However, since the gp 130 protein does not associate with the SH2 domain of p85 after cytokine-treatment of cells, nor does it contain consensus binding sites for p85 SH2, intermediate signal proteins must be operating. Possibilities include ras, JAK-1, STAT-3, or vav. All are potentially activated by IL-6 CatlettFalcone et al., 1999; Lee et al., 1997) and all are capable of activating PI3-kinase/AKT downstream (Pfeer et al., 1997; Oh et al., 1998; Shigematsu et al., 1997; Franke et al., 1995; Foschi et al., 1997) . It will be particularly clinically relevant if ras is an important upstream activator as up to 40% of myeloma tumor cell populations harbor oncogenic ras mutations.
Interleukin-6 is known to stimulate myeloma cell proliferation as well as survival when challenged with anti-fas, serum starvation, doxorubicin or dexamethasone. Some experimental evidence indicates these two cytokine-dependent eects are dissociable and, thus, possibly mediated by distinct mechanisms (Lichtenstein et al., 1995) . To ®rst assess the role of AKT in MM cell proliferation, we enhanced or inhibited AKT activation/activity by gene transfer using adenoviral vectors. The active E40K construct signi®cantly increased cell growth in vitro, indicating a role for AKT in MM cell expansion. Although IL-6 was capable of further AKT activation in E40K-transfected cells, this was minimal and possibly due to stimulation of the remaining endogenous AKT rather than the E40K protein. In any case, the ability of IL-6 to stimulate MM cell expansion in E40K-transfected cells was not greater than the IL-6 eect in controltransfected cells when comparing proliferation indices. An additional possibility for this lack of increased proliferation index is that, at high levels of activated AKT such as induced by E40K transfection, additional IL-6-dependent pathways may become rate-limiting for induction of cell growth and they are equally stimulated in E40K and control-transfected cells. For example, prior work (Ogata et al., 1997) con®rms Although we could not show the active AKT construct enhances IL-6-stimulated growth, the results of experiments utilizing the dominant negative PH AKT con®rm that AKT mediates this cellular response. Interruption of AKT function in these cells in the absence of IL-6 had no eect on cell growth in vitro or on cell cycle analysis (32% S phase in control and 27% S phase in PH-expressing cells, (Figure 4) ). These data are consistent with the fact that there is little basal AKT activation in AF-10 cells. However, the PH construct prevented the IL-6-induced increase in cell numbers as well as the increase in fraction of cells in S phase (Figure 4) . In a previous study (Tu et al., 2000) , we showed a similar inhibition of IL-6-induced proliferation of AF-10 cells when cultured with wortmannin, the PI 3-kinase inhibitor. There was no increase in apoptotic death in PH-expressing cells following IL-6 stimulation, either assayed by Trypan blue staining, cell morphology, or DNA content analysis. Collectively, these data clearly indict PI 3-kinase and AKT as critical eectors of the IL-6-induced proliferative response. Two possible AKT substrates that might mediate this proliferative eect are the p70S6kinase and 4E-BP1 translational repressor. When phosphorylated downstream of AKT (possibly via the mTOR intermediate (Sekulic et al., 2000) ), both p70 and 4E-BP1 would promote translation of proteins required for cell cycle transit (Jeeries et al., 1994; Rosenwald et al., 1995) . In preliminary experiments we have identi®ed IL-6-induced activation of p70S6kinase activity and 4E-BP1 phosphorylation in AF-10 cells, which is wortmannin sensitive and inhibited by the PH dominant negative AKT.
Initial experiments with the E40K active AKT demonstrated a clear AKT-dependent resistance to the apoptotic eects of dexamethasone but not to antifas or doxorubicin. As dexamethasone is a frequently used and often eective drug in myeloma patients, the high levels of AKT activation we found in patient marrow tumor cells (Hsu et al., 2001 ) may play a role in dexamethasone-resistance. To test if AKT played a role in the well documented ability of IL-6 to protect myeloma cells against dexamethasone, we used the same PH dominant negative vector, transfecting dierent myeloma cell lines, where we could isolate cytokine-dependent eects on apoptosis. The results demonstrate that IL-6-induced protection against dexamethasone in these cells was due to AKTindependent pathways. However, this does not rule out the possibility that AKT may mediate cytokineinduced protection of MM cells against dexamethasone in other MM cell lines or when other cytokines are used. For example, IGF-1 treatment of 8226 or OCIMy5 cells protects them against dexamethasone and such protection is inhibited by co-culture with the PI3-kinase inhibitors wortmannin and Ly294002 (Tu et al., 2000) . One dierence between these cytokine treatments is that AKT activation induced by IGF-1 in these MM cell lines is much more impressive than that induced by IL-6 (Tu et al., 2000) . A second theoretical possibility is that IL-6 can induce additional non-AKT anti-apoptotic pathways (like STAT3 (Catlett-Falcone et al., 1999) ), which IGF-1 can not.
In summary, these results indicate activation of AKT occurs in multiple myeloma plasma cells. Because of its central location, activating diverse downstream proliferative and anti-apoptotic pathways, AKT is a promising target for future molecular-based therapy. In addition, the frequent activation in myeloma tumor cells compared to nonmalignant cells suggests a therapeutic window may exist in patients.
Materials and methods
Myeloma cells
The MM cell lines 8226, OCI-My5, and AF-10 were kind gifts from Drs J Epstein (University of Arkansas), H Messner (University of Toronto), and James Berenson (UCLA). The lines were maintained in vitro as described previously (Lichtenstein et al., 1995; Xu et al., 1998; Tu et al., 2000) .
Reagents
Recombinant IL-6 was purchased from R&D Systems (Minneapolis, MN, USA). Phospho-speci®c and total anti-AKT antibodies were purchased from Biosource, Inc. and New England Biolabs. All other reagents were purchased from Sigma Chemical Co. (St. Louis, MO, USA) unless otherwise speci®ed.
Expression constructs and transfections
The N-terminus AKT construct HA-AKT(PH), which includes the PH domain but lacks the kinase domain, and the HA-E40K construct, which contains a point mutation in its PH domain, have been previously described (Soonyang et al., 1997) . The PH functions as a dominant-negative inhibitor of endogenous AKT (Soonyang et al., 1997) , and the E40K possesses enhanced AKT activity (Aoki et al., 1998) . Both contain hemagglutinen (HA) epitope tags (Soonyang et al., 1997) . A recombinant adenovirus that encodes HA-AKT(PH) or HA-E40K was generated by homologous recombination in bacteria as previously described (He et al., 1998) . The HAtagged constructs were ®rst cloned into pAdTrack-CMV which also contains the green¯uorescent protein (GFP) gene. The resultant construct was linearized and transformed with the supercoiled adenoviral vector, pAdEasy-1, into E. coli and recombinants selected in kanamycin and screened by restriction endonuclease digestion. The recombinant adenovirus was then transfected into 293 cells. Control pAdTrack-CMV recombinant virus was generated in identical fashion but without transgene insertion. Myeloma cells were transduced with adenovirus at varying MOIs for 2 h. Adenovirus was then washed away and cells were resuspended in media with low serum concentration (1% FCS) to minimize proliferation. At 24 and 48 h, EGFP¯uorescence demonstrated that 485% of cells were successfully transfected when using MOIs between 10 and 100. Expression of HA-AKT(PH) was also con®rmed by Western anti-HA immunoblotting.
Western blot analysis
Protein was extracted and separated by 12.5% SDS ± PAGE as previously described (Lichtenstein et al., 1995; Tu et al., 2000) . Proteins were transferred to polyvinylidene di¯uoride membranes and phosphorylated as well as total AKT proteins were detected as previously described (Lichtenstein et al., 1995; Tu et al., 2000) . Relative expression of phosphorylated AKT was determined by densitometry.
AKT kinase assay
The AKT in vitro kinase assay utilized a non-radioactive kit purchased from New England Biolabs. AKT was ®rst immunoprecipitated from cell extracts and then incubated with GSK-3 fusion protein in the presence of ATP and kinase buer. AKT-dependent GSK-3 phosphorylation was then measured by immunoblotting using a phospho-GSK-3 antibody that recognizes GSK-3 when phosphorylated.
Treatment of cells and determination of cell numbers
MM cells were cultured at 2610 5 /ml in 6 or 12-well plates in complete media. IL-6 was added to some groups at a concentration of 5 ng/ml. After 24 ± 72 h of culture, cells were harvested and cytotoxicity (an assessment of proliferation as well as survival) determined by Trypan blue staining or MTT assays as previously described (Aparicio et al., 1998) . IL-6-induced expansion of cell numbers was described as a proliferation index, calculated as number of viable cells (or OD in MTT assays) in experimental groups divided by number of cells (or OD) in the control group (no IL-6). To test sensitivity to cytotoxicity, cells were treated with increasing concentrations of anti-fas antibody (clone CH11, Upstate Biotech.), doxorubicin, or dexamethasone. At varying time points, per cent cytotoxicity was determined as follows: (1 ± OD (or viable cell count) or exp group/OD (or viable cell count) of control group6100). The LD50 (concentration of drug inducing 50% cytotoxicity) was determined from extrapolation of results of MTT assays, whereby percentage cytotoxicity was plotted against log 10 concentration. To speci®cally test sensitivity to apoptosis,¯ow cytometry was performed on annexin-V-stained cells (below).
Flow cytometry
For cell cycle analysis of adenoviral vector-transfected cells, MM cells were stained with hypotonic propidium iodide (50 mg/ml in 0.1% sodium citrate) and 0.1% Triton X-100 for 1 h at 48C. Cells were kept in the dark at 48C before analysis. Cell cycle distribution was determined by analysing 10 000 ± 15 000 events on a FACScan¯ow cytometer (Becton Dickinson, San JoseÂ , CA, USA). The DNA data were ®tted to a cell cycle distribution analysis by use of the MODFIT program for MAC V2.0.
Apoptosis assay
Neo-expression of membrane annexin-V was used to determine per cent apoptosis. Since transfected cells expressed green¯uorescence due to expression of EGFP, phycoerythrin (PE)-conjugated annexin-V (Pharmingen) was employed. Cells were stained with PE-annexin-V and 7-amino-actinomycin-D (7-AAD) according to the vendor's directions. Early apoptotic cells were identi®ed by¯ow cytometry as PEannexin-V-positive and 7-AAD-negative.
Statistics
The t-test was used to determine signi®cance of dierences between groups.
